A novel microRNA signature for the detection of melanoma by liquid biopsy

[1] Saginala K(2021)Epidemiology of melanoma Med Sci. 9 63-36

[2] Barsouk A(2019)Five-Year outcomes with dabrafenib plus trametinib in metastatic melanoma N Engl J Med. 381 626-35

[3] Aluru JS(2021)5-Year Outcomes with cobimetinib plus vemurafenib in Clin Cancer Res. 27 5225-44

[4] Rawla P(2020) V600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study Eur J Cancer. 126 33-51

[5] Barsouk A(2019)Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma Lancet Oncol. 20 1239-46

[6] Robert C(2019)Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study N Engl J Med. 381 1535-73

[7] Grob JJ(2021)Five-year survival with combined nivolumab and ipilimumab in advanced melanoma Cancers 30 656-57

[8] Stroyakovskiy D(2015)Biomarkers for diagnosis, prognosis and response to immunotherapy in melanoma Sci Rep. 161 1046-43

[9] Karaszewska B(2021)Plasma extracellular RNA profiles in healthy and cancer patients Wiley Interdiscip Rev RNA. 2 e201800205-18

[10] Hauschild A(2019)microRNA-based diagnostic and therapeutic applications in cancer medicine Cell Metab. 126 1139-74

[1] Saginala K(2021)Epidemiology of melanoma Med Sci. 9 63-36

[2] Barsouk A(2019)Five-Year outcomes with dabrafenib plus trametinib in metastatic melanoma N Engl J Med. 381 626-35

[3] Aluru JS(2021)5-Year Outcomes with cobimetinib plus vemurafenib in Clin Cancer Res. 27 5225-44

[4] Rawla P(2020) V600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study Eur J Cancer. 126 33-51

[5] Barsouk A(2019)Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma Lancet Oncol. 20 1239-46

[6] Robert C(2019)Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study N Engl J Med. 381 1535-73

[7] Grob JJ(2021)Five-year survival with combined nivolumab and ipilimumab in advanced melanoma Cancers 30 656-57

[8] Stroyakovskiy D(2015)Biomarkers for diagnosis, prognosis and response to immunotherapy in melanoma Sci Rep. 161 1046-43

[9] Karaszewska B(2021)Plasma extracellular RNA profiles in healthy and cancer patients Wiley Interdiscip Rev RNA. 2 e201800205-18

[10] Hauschild A(2019)microRNA-based diagnostic and therapeutic applications in cancer medicine Cell Metab. 126 1139-74